Nonetheless, our data suggest that AMG 330 is broadly active against human AML, and support our conclusion that it should be clinically explored in patients with AML and, by extrapolation, perhaps other CD33+ hematopoietic malignancies. Here, CD33 is linked to acute myeloid leukemia.